Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial.
Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial.
复制标题
DOI：
10.1155/2022/4090807
复制
发表时间：
2022
影响因子：
4.3
通讯作者：
Halaris A
中科院分区：
文献类型：
--
作者：
Penckofer S;Ridosh M;Adams W;Grzesiak M;Woo J;Byrn M;Kouba J;Sheean P;Kordish C;Durazo-Arvizu R;Wallis D;Emanuele MA;Halaris A
确定维生素D3补充剂在减少2型糖尿病（T2 D）、抑郁症和低维生素D女性抑郁症状方面的有效性和安全性。 在这项双盲随机活性对照试验中，根据流行病学研究中心抑郁（CES-D）量表评估，具有显著抑郁症状的女性每周接受口服维生素D3补充剂（50，000 IU）或活性对照品（5，000 IU），持续6个月。在基线、3个月和6个月时测量维生素D、25-羟基维生素D [25（OH）D]和抑郁症的评估。 共有129名女性被随机分组，其中119名完成了研究（57名低剂量，62名高剂量）。参与者在基线时的平均25（OH）D和HbA 1c分别为20.8 ng/mL和7.8%。他们是多样化的（48%黑人），平均年龄为50岁，T2 D约8年。在完成维生素D3补充后，血清25（OH）D水平增加了50，000 IU（+34 ng/mL）和5，000 IU（+10 ng/mL）。各治疗剂量的CES-D评分无差异。总体而言，抑郁症状随着时间的推移而显著改善，平均CES-D下降12.98分（95% CI：-15.04至-10.93; p < 0.001）。在中度基线抑郁症状的女性中，接受较低剂量的女性在随访时的抑郁评分名义上低于接受较高剂量队列的女性。在有严重基线抑郁症状的女性中，无论剂量如何，随访抑郁评分的改善是相同的。 维生素D3补充剂治疗具有显著症状和低维生素D的T2 D女性抑郁症状的剂量效应没有差异。无论剂量如何，参与者的情绪都会随着时间的推移而改善。需要进一步研究维生素D在共病人群中的抑郁症状。
To determine the efficacy and safety of vitamin D3 supplementation in reducing depressive symptoms in women with type 2 diabetes (T2D), depression, and low vitamin D. In this double-blind randomized active comparator-controlled trial, women with significant depressive symptoms as assessed by the Center for Epidemiologic Studies Depression (CES-D) scale received weekly oral vitamin D3 supplementation (50,000 IU) or an active comparator (5,000 IU) for 6 months. Assessments of vitamin D, 25-hydroxyvitamin D [25 (OH) D], and depression were measured at baseline, 3 months, and 6 months. A total of 129 women were randomized, from which 119 completed the study (57 in lower dose and 62 in higher dose). Participants had an average 25 (OH) D and HbA1c of 20.8 ng/mL and 7.8%, respectively, at baseline. They were diverse (48% Black) and had a mean age of 50 and T2D for about 8 years. Upon completion of vitamin D3 supplementation, serum 25 (OH) D levels increased with 50,000 IU (+34 ng/mL) and 5,000 IU (+10 ng/mL). There was no difference in CES-D scores by treatment dose. Overall, depressive symptoms significantly improved over time with an average CES-D decline of 12.98 points (95% CI: −15.04 to −10.93; p < 0.001). Among women with moderate baseline depressive symptoms, those receiving the lower dose had nominally lower depression scores at follow-up than those in the higher dose cohort. Among women with severe baseline depressive symptoms, the improvement in follow-up depression scores was the same regardless of dose. There was no difference in the dosing effect of vitamin D3 supplementation for the treatment of depressive symptoms in women with T2D who present with significant symptoms and low vitamin D. Regardless of the dose, participants' mood improved over time. Further study of vitamin D to target depressive symptoms in comorbid populations is needed.
登录
查看更多内容
DOI：
10.3102/10769986024001070
发表时间：
1999-03-01
影响因子：
2.4
作者：
Hedeker, D;Gibbons, RD;Waternaux, C
通讯作者：
Waternaux, C
影响因子：
7.2
作者：
Lunghi, C.;Zongo, A.;Guenette, L.
通讯作者：
Guenette, L.
影响因子：
2.2
作者：
Brieler, Jay A.;Lustman, Patrick J.;Schneider, F. David
通讯作者：
Schneider, F. David
影响因子：
5.4
作者：
Fornari, R.;Francomano, D.;Migliaccio, S.
通讯作者：
Migliaccio, S.
影响因子：
120.7
作者：
Bot, Mariska;Brouwer, Ingeborg A.;Mauche, Nicole
通讯作者：
Mauche, Nicole